Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COPD Drug Dose Selection May Face Greater Scrutiny In Arcapta’s Wake

Executive Summary

FDA’s lingering concerns about the appropriate dose for Novartis’ chronic obstructive pulmonary disease therapy Arcapta Neohaler (indacaterol) suggest the agency will take a harder line on dosing data requirements for new COPD treatments, particularly when they have not first been approved in asthma.
Advertisement

Related Content

Ilaris Gout Review Reflects Tougher FDA Approach To Biologic Dosing Safety
Dosing-Related Economics Arise During FDA Panel’s Arcapta Review
Arcapta Quality-Of-Life Benefit For Higher Dose Isn't Enough Given Efficacy Data
Arcapta Quality-Of-Life Benefit For Higher Dose Isn't Enough Given Efficacy Data
Dosing-Related Economics Arise During FDA Panel’s Arcapta Review
Arcapta Quality Of Life Data For High Dose Cannot Overcome Efficacy Questions
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Novartis Resubmits Onbrez To FDA; Touts Comparative Trial Against Spiriva
Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree
Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol

Topics

Advertisement
UsernamePublicRestriction

Register

PS053202

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel